As discussed later, a more aggressive surgical resection for glioma patients with an IDH mutation is associated with greater survival benefit [178,179,180], making simple assays capable of performing intraoperatively valuable tools for clinicians seeking to use this information to guide the extent of resection. The gene discussed is IDH1; the disease is central nervous system cancer.